1George JN. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol, 2012, 87(suppl 1 ) :s88-s91.
2Sadler JE, Moake JL, Mijata T, et al. Recent advances in throm- botic thrombocytopenic purpura. Hematology Am Soc Hematol Edue Program, 2004, 407-423.
3Kotbi N, Han B, Cheng D, et al. Opana(() ER induced throm- botic thrombocytopenic purpura. Int Med Case Rep, 2015, 8 : 97-98.
4Nazzal M, Sail F, Arma F, et al. Micafungin-induced thrombotic thrombocytopenie purpura: a case report and review of the litera- ture. Am J Ther, 2011,18(6) :258-260.
5Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med, 2014,5:15-23.
6Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat, 2010 ; 31 ( 1 ) : 11-19.
8Tasaki T, Yamada S, Nabeshima A, et al. An autopsy case of my- ocardial infarction due idiopathic thrombotic thrombocytopenic purpura. Diagn Pathol, 2015, 10:52.
9Shenkman B, Einav Y. Thrombotic thrombocytopenic purpura and other thrombotic microanglopathic hemolytic anemias: Diagnosis and classification. Autoimm Rev, 2014, 13(4-5):584-586.
10Knobl P, Rinlelen C, Kome RG, et al. Plasma exchange for treat- ment of thrombotic thrombocytopenic purpura critically ill patients. Intensive Care Med, 1997,23 ( 1 ) :44-50.
二级参考文献20
1Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura[J]. Blood, 2011, 118(7):1746-1753.
2Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura[J]. Blood, 2008, 112(1):11-18.
3Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group[J]. Ann Intern Med, 1995, 122(8): 569-572.
4Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features[J]. Br J Haematol, 2008, 142(5):819-826.
5Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 andmanti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission[J]. Haematologica, 2008, 93(2): 232-239.
6Kremer Hovinga JA, L?mmle B. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura[J]. Hematology Am Soc Hematol Educ Program, 2012, 2012:610-616.
7Ferrari S, Mudde GC, Rieger M, et al. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2009, 7(10): 1703-1710.
8Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias[J]. Br J Haematol, 2003, 120(4):556-573.
9Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives[J]. J Blood Med, 2014, 5:15-23.
10Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013:292-299.
